Targeting of innate immune response to tumor site
US9358307B2 · kind B2 · utility
5Cited by
2References
20Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jan 25, 2009 |
| Grant date | Jun 7, 2016 |
| Priority date | — |
| Expiry date | Jul 13, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/40
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides microparticles or nanoparticles for treatment of tumors comprising: (i) a targeting agent to the tumor or the tumor environment; and (ii) at least one inducer that stimulates a desired immune response in the tumor environment, leading to tumor apoptosis, wherein components (i) and (ii) are non-covalently or covalently attached to the surface of said microparticles or nanoparticles. The targeting agent is an agent that recognizes and binds to an antigen, a receptor or other molecules found on the surface of tumor cells or in the tumor environment and are preferably antibodies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.